Low density lipoprotein future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 29: | Line 29: | ||
|Inhibition of Apo B || || || || || || || | |Inhibition of Apo B || || || || || || || | ||
|- | |- | ||
|PCSK9 | |PCSK9 Inhibition|| || || || || || || | ||
|- | |- | ||
|MTP Inhibition || || || || || || || | |MTP Inhibition || || || || || || || | ||
| Line 46: | Line 46: | ||
|- | |- | ||
| || || || || || || || | | || || || || || || || | ||
|} | |} | ||
Revision as of 15:07, 2 October 2013
|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Low density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Low density lipoprotein future or investigational therapies |
|
FDA on Low density lipoprotein future or investigational therapies |
|
CDC on Low density lipoprotein future or investigational therapies |
|
Low density lipoprotein future or investigational therapies in the news |
|
Blogs on Low density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for Low density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
The Unmet Need Driving Research Into Lowering LDL
Investigational Therapies
Inhibition of Apolipoprotein B production
PCSK9 Inhibition
Monoclonal Antibodies
Antisense Oligonucleotides (ASO)
Small Interfering RNAs (SiRNAs)
Microsomal Triglyceride Transfer Protein (MTP) Inhibition
Thyromimetics
Squalene Synthase Inhibition
Table
| Class | Drug Company | Agent Name | Mechanism of Action | Efficacy on Lowering LDL-C | Route of Administration | Adverse Effects | Published Clinical Trials |
|---|---|---|---|---|---|---|---|
| Inhibition of Apo B | |||||||
| PCSK9 Inhibition | |||||||
| MTP Inhibition | |||||||
| Thyromimetics | |||||||
| Squalene Synthase Inhibitors | |||||||
References